4 recruiting, 1 not yet recruiting. 2 Early Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Plasma Cell Leukemia (PCL): new trials by email Literature Review of Plasma Cell Leukemia (PCL) trials Research Report on Plasma Cell Leukemia (PCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-09-15 | 2026-09-18 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma IASO104 - Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2026-02-15 | 2026-01-20 |
| IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia IL-15-armored CAR-T cells - Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | The First Hospital of Jilin University | 25 | 2025-12-29 | 2026-04-03 |
| Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research Metabolically Armed BCMA CAR-T cells. - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Early Phase 1 | Recruiting | Anhui Provincial Hospital | 36 | 2025-06-23 | 2025-07-25 |
Leukemia, Plasma Cell (5) · Multiple Myeloma (4) · Frailty (1) · Immunoglobulin Light-chain Amyloidosis (1) · Neoplasms, Plasma Cell (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Blood Protein Disorders (4) · Cardiovascular Diseases (4) · Hemorrhagic Disorders (4) · Hemostatic Disorders (4) · Neoplasms, Plasma Cell (4) · Paraproteinemias (4) · Vascular Diseases (4)
Lenalidomide (2) · Bortezomib (1) · Dexamethasone (1) · Focal Adhesion Protein-Tyrosine Kinases (1) · Fumigant 93 (1) · daratumumab (1) · darlin protein, Dictyostelium (1) · isatuximab (1) · talquetamab (1)
Institute of Hematology & Blood Diseases Hospital, China (2) · Anhui Provincial Hospital (1) · The First Hospital of Jilin University (1) · University of Leeds (1)
China (3) · United Kingdom (1)
Charlotte Pawlyn (1) · Gordon Cook (1)